Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Other Non-Current Assets (2020 - 2025)

Legend Biotech filings provide 6 years of Other Non-Current Assets readings, the most recent being $12.4 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets fell 4.62% to $12.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.4 million, a 4.62% decrease, with the full-year FY2025 number at $12.4 million, down 4.62% from a year prior.
  • Other Non-Current Assets hit $12.4 million in Q4 2025 for Legend Biotech, up from $11.0 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $24.6 million in Q1 2022 to a low of $3983.0 in Q1 2021.
  • Median Other Non-Current Assets over the past 5 years was $3.3 million (2021), compared with a mean of $5.5 million.
  • Biggest five-year swings in Other Non-Current Assets: skyrocketed 618102.36% in 2022 and later plummeted 95.69% in 2023.
  • Legend Biotech's Other Non-Current Assets stood at $5.1 million in 2021, then plummeted by 71.11% to $1.5 million in 2022, then increased by 0.4% to $1.5 million in 2023, then surged by 770.73% to $13.0 million in 2024, then fell by 4.62% to $12.4 million in 2025.
  • The last three reported values for Other Non-Current Assets were $12.4 million (Q4 2025), $11.0 million (Q3 2025), and $5.7 million (Q2 2025) per Business Quant data.